Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy
- 17 July 2023
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 955, 175913
Abstract
No abstract availableKeywords
This publication has 135 references indexed in Scilit:
- Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagyNature, 2014
- Regulation of Ferroptotic Cancer Cell Death by GPX4Cell, 2014
- Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenibInternational Journal of Cancer, 2013
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κBJournal of Neurochemistry, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drugLeukemia, 2001
- The effect of bcnu (carmustine) on tissue glutathione reductase activityToxicology Letters, 1983